6-APB is a novel entactogen substance of the benzofuran class. It is structurally related to entactogens like MDA, MDMA, 5-APB, and 5-MAPB.

6-(2-Aminopropyl)benzofuran, Benzofury

Subjective effects include anxiety suppression, disinhibition, muscle relaxation, and euphoria. 6-APB’s effects are commonly compared to those of MDA and other entactogens. 6-APB has paradoxical physical effects, being both stimulating and sedating, with a “couch-locking” effect and moderate to powerful euphoric body sensations. It can cause increased heart rate, body temperature, and dehydration, along with visual enhancements like color and pattern recognition, and mild hallucinations at higher doses. Cognitive effects include empathy, sociability, euphoria, and mental stimulation, with potential after-effects such as anxiety, cognitive fatigue, and irritability.

6-APB was first synthesized in 1993 by David E. Nichols as a potential non-neurotoxic alternative to MDMA. However, recreational human use was not documented until over a decade later, where it briefly entered the rave scene and global research chemical market. It was sold along with other novel benzofuran entactogens under the name “Benzofury” before its sale and import were subsequently banned.